Investment
Features
FeesSafety
Academy
More
Pluang+

Dynex Capital models 20-25% returns on new mortgage-backed securities despite Q3 losses

Market News
19 Oct 2026
Tokenpost
View Source
Neutral
Dynex Capital models 20-25% returns on new mortgage-backed securities despite Q3 losses

Dynex Capital, a mortgage real estate investment trust, projects static returns on new mortgage-backed securities at 20% for lower-coupon and 25% for current-coupon securities, driven by wider spreads and improved conditions. These modeled returns assume about 10 times leverage and apply to new investments hedged with interest rate swaps. However, the company's existing portfolio faced challenges in Q3, with book value dropping 15.4% and a total economic return of negative 11.4%, mainly due to wider mortgage-backed securities spreads. Dynex raised $384 million in capital during the quarter and ended with $1.3 billion in liquidity, positioning it for future investments despite recent losses.

Dynex Capital's projected static ROE on new mortgage-backed securities provides context for readers interested in financial returns. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 20, 2026 07:21 WIB: out of 50 major cryptocurrencies, 32 rose and 17 fell today. Notable movers include ATOM at Rp31.312 (+3.71%, 24% Sell / 76% Buy), DOT at Rp20.639 (+3.26%, 83% Sell / 17% Buy), and SNX at Rp3.868 (+3.17%, 99% Sell / 1% Buy).

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
1 hour ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
1 hour ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
2 hours ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
3 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App